• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » GOP senators grill FDA devices chief Shuren

GOP senators grill FDA devices chief Shuren

November 16, 2011 By Arezu Sarvestani

Richard Burr in a Senate hearing

Sen. Richard Burr (R-NC)

FDA Center for Devices & Radiological Health chief Dr. Jeffrey Shuren got pummeled by Republican members of the Senate Health, Education, Labor & Pensions committee this week.

Shuren took tough questions from North Carolina’s Sen. Richard Burr (R), who called the agency out on its failure to meet goals associated with medical device user fee negotiations during a congressional hearing on medical devices, protecting patients and promoting innovation.

"Negotiations suggest that the agency is seeking a more than 250 percent increase in user fees from current levels," Burr said. "Let me ask you – would you agree to pay somebody any money at all, much less a 250 percent increase over what they’re currently paying, when the terms of what you’re paying for aren’t being met?"

Burr also accused the agency of "bashing" the industry for the increase in application review times, which Shuren insisted wasn’t the CDRH’s position on the root of the problem.

"We have not been out there saying that the problems are all due to industry," Shuren told the committee. "I’ve been saying for a long time now that, actually, the problems are multi-factorial and that a good part of it is due to the FDA."

"It troubles me, and I would hope that it would trouble you, that most companies across this country tell horrific stories about going through the approval process at the FDA," Burr retorted, adding that the concerns companies and venture capitalists voice about unpredictability at the agency need to be weighed into decisions on how to improve the process.

Shuren added that many of the agency’s goals involve improving procedures at the FDA to make the device review process more efficient and easier to understand, but he did put some of the responsibility on the industry’s shoulders.

"We do get, from a number of companies, submissions that are of poor quality," Shuren said. Unlike the pharmaceutical review process, in which bad submissions are sent back to the manufacturer, the CDRH works with companies to improve the application, he explained. "When we take in a submission that may not be of sufficient quality and we’re going to work with them, we end of doing some of the work for the company."

Sen. Orrin Hatch (R-Utah) closed the session by inquiring about the time and effort the FDA has spent on the 510(k) process, "a program that really seemed to be working pretty dog-gone well," and asking what the agency planned to do about application review times that had grown by 50 percent to 100 percent in some cases.

Dr. Jeffrey Shuren

Dr. Jeffrey Shuren

"When U.S. industry is losing its competitive edge and patients are waiting longer and longer for treatments and cures, that’s a matter of great concern for me," Hatch said. "I think we’re falling behind the rest of the world in approvals, yet we have some of the most imaginative people working in this country."

Burr has been an active participant in discussions concerning medical devices review times. He lent his signature to a letter led by fellow Minnesota Sen. Amy Klobuchar to FDA head Dr. Margaret Hamburg, raising concerns over "increased review times, inconsistent expectations, and poor communication from the FDA."

The North Star State is home to some of the world’s largest med-tech companies, including Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ).

The hearing followed the introduction of the Patient Access to Medical Innovation Act, a bill led by another Minnesota legislator, Sen. Al Franken (D), aimed at increasing incentives for devices for treating rare diseases and relaxing conflict-of-interest standards for medical experts serving on med-tech review panels.

Filed Under: Food & Drug Administration (FDA) Tagged With: 510(k) reforms

In case you missed it

  • DTW Podcast: Can AI, advanced imaging and robotics “democratize” surgery?
  • First OTC molecular test for COVID-19 gains FDA nod
  • Private equity firm GTCR forms Epselon Global to acquire healthcare businesses
  • Former Abbott sales director’s age discrimination suit can proceed
  • Second Sight gains FDA nod for retinal system that may never be produced
  • Abbott wins EUA for COVID-19, flu, RSV combo assay
  • Colfax to split to create new orthopedic device giant
  • Iridex, Topcon seal eye care deal
  • SmileDirectClub dips on missed Q4 projections
  • MedAlliance nabs FDA breakthrough nod for drug-eluting coronary balloon
  • Medtronic launches DCB for dialysis patients in Japan
  • Acuitive Technologies gains FDA nod for ligament reconstruction devices
  • Alphatec posts mixed-bag Q4 results
  • Senseonics sinks on mixed bag Q4, massive bottom-line slide
  • Asensus Surgical finalizes name change from TransEnterix, debuts NYSE ticker
  • Organ-chips could streamline drug development, but hurdles remain
  • Ivermectin not supported for mild COVID-19, study says

RSS From Medical Design & Outsourcing

  • First OTC molecular test for COVID-19 gains FDA nod
    The FDA today issued its first emergency use authorization for a molecular COVID-19 diagnostic test for at-home use without a prescription. The Cue Health COVID-19 Test for Home and Over The Counter (OTC) use is a molecular nucleic acid amplification test designed to detect genetic material from the SARS-CoV-2 virus in the nostrils. The authorized… […]
  • A wearable jaundice monitor for newborns?
    Researchers in Japan say they have developed the first wearable device to precisely monitor jaundice, a yellowing of the skin caused by elevated bilirubin levels in the blood that can cause severe medical conditions — even death — in newborns. Jaundice can be treated easily by irradiating the infant with blue light that breaks bilirubin… […]
  • Plastikos to double size of medical manufacturing operation
    Plastikos announced today that the second phase of construction on its Plastikos Medical plant will begin this month. The Erie, Pa.-based company completed the first building in its medical business in 2019 and has added 10 medical injection molding machines since then. The second building will more than double the size of the current ISO-7 cleanroom… […]
  • Paxxus sealant updated for EU-MDR
    Paxxus announced this week that its Chameleon color-changing package seal indicator technology now works with uncoated Tyvek used to package medical devices. Addison, Ill.-based Paxxus said it updated the technology in advance of a new packaging regulation set to go into effect in the EU in May. Chameleon now shows a vivid color-seal indicator when… […]
  • Medtronic hiring Walmart exec to run its supply chain
    Medtronic (NYSE:MDT) CEO Geoff Martha announced that the company is appointing Greg Smith as EVP of global operations and supply chain. In a LinkedIn post today, Martha wrote: “I’m pleased to share that Greg Smith, Executive Vice President of U.S. Supply Chain for Walmart, is joining Medtronic on April 5 as Executive Vice President of… […]
  • Philips and Disney want to make MRIs easier for children: Here’s how
    Royal Philips (NYSE:PHG) announced today that it is teaming up with Disney to test the effects of custom-made animation to create a relaxing atmosphere for young patients. Amsterdam-based Philips will collaborate with The Walt Disney Company EMEA to see whether the animation, including specially-made Disney stories within Philips’ Ambient Experience, creates a relaxing atmosphere to improve… […]
  • Origami Surgical gains FDA clearance for robotic suturing devices
    Origami Surgical today announced that the FDA has granted 510(k) clearance for three new types of sutures for its StitchKit robotic surgery platform. The company describes StitchKit as a patented suture delivery and retrieval system designed so sutures are efficiently inserted and needles are safely removed from the surgical field. StitchKit also allows the robotic… […]
  • NAMSA acquires American Preclinical Services
    Contract research organization NAMSA today announced its acquisition of Minneapolis-based American Preclinical Services (APS). This purchase follows NAMSA’s acquisition of New York-based Syntactx, a clinical research services CRO, in January. The acquisition will provide NAMSA customers with a broader range of laboratory models and analysis tools, including innovative surgical instrumentation and several state-of-the-art catheterization labs,… […]
  • 5 reasons Medtronic’s CEO is optimistic about the future
    Nearly a year after Geoff Martha took over the corner office at Medtronic, the world’s largest medical device company is transforming. In a recent interview with our DeviceTalks Weekly podcast, Martha detailed Medtronic‘s major reorganization, its shift in corporate culture and more. Martha was also highly pleased about Medtronic’s recent Q3 earnings results. Here are… […]
  • Medtronic is changing a lot: Here’s what you need to know
    CEO Geoff Martha says Medtronic‘s ongoing corporate restructuring will position the company to compete better with medical device rivals, freeing the front-line forces from earlier entanglements. But the change will also create new opportunities for Medtronic employees at the company and elsewhere. In a far-ranging interview with the DeviceTalks Weekly podcast, Martha reviewed the company’s… […]
  • Pharma’s been slow to adopt Industry 4.0 — but that could change
    The pharma industry has been relatively slow to embrace concepts such as Industry 4.0, but COVID-19 is serving as a catalyst for sweeping changes within the industry. The philosophy has roots in a German framework that prioritizes digitization to drive manufacturing efficiency, promising that cyber-physical systems will usher in the next industrial revolution. The Industry… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS